Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans
CEO Vohra Talks Strategy With Scrip
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.
You may also be interested in...
Expectations will be high after the COVID-19 product IP waiver plan took a big step forward and G7 leaders prepare for discussions on the global recovery from coronavirus, tackling climate change and other weighty subjects.
Cipla is no novice in the vaccines segment and a potential link up for Moderna’s mRNA COVID-19 vaccine or with other firms could add an important lever in the 80-plus year-old Indian firm’s overall strategic thrust. Management has all along maintained a positive tone for coronavirus vaccine alliances.
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.